ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) Sees Large Decrease in Short Interest

ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) was the recipient of a significant decline in short interest in the month of January. As of January 15th, there was short interest totalling 11,800 shares, a decline of 71.8% from the December 31st total of 41,800 shares. Based on an average daily trading volume, of 12,100 shares, the short-interest ratio is currently 1.0 days.

ProShares UltraShort Nasdaq Biotechnology Trading Down 1.9 %

Shares of NASDAQ:BIS traded down $0.31 on Thursday, hitting $16.41. The company had a trading volume of 4,614 shares, compared to its average volume of 6,485. ProShares UltraShort Nasdaq Biotechnology has a 1 year low of $14.05 and a 1 year high of $21.10. The firm’s 50-day simple moving average is $17.24 and its two-hundred day simple moving average is $15.90.

ProShares UltraShort Nasdaq Biotechnology Increases Dividend

The company also recently disclosed a dividend, which was paid on Tuesday, December 31st. Investors of record on Monday, December 23rd were issued a $0.2064 dividend. This is a positive change from ProShares UltraShort Nasdaq Biotechnology’s previous dividend of $0.15. The ex-dividend date of this dividend was Monday, December 23rd.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in ProShares UltraShort Nasdaq Biotechnology stock. Jane Street Group LLC bought a new position in ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 10,520 shares of the company’s stock, valued at approximately $158,000. Jane Street Group LLC owned approximately 4.78% of ProShares UltraShort Nasdaq Biotechnology at the end of the most recent quarter.

ProShares UltraShort Nasdaq Biotechnology Company Profile

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period.